BACKGROUND: Topical immunotherapy using potent contact allergens, such as @entity25183 ( @entity25183 ), can be used to treat @entity1665 areata. However, there are conflicting reports regarding the best protocol for its administration, particularly with regard to the necessity of an eczematous response after the initial sensitization treatment. OBJECTIVES: We sought to assess the impact of initial sensitization on subsequent hair regrowth. METHODS: This is a retrospective review of the use of @entity25183 in the treatment of @entity1665 areata in 14 @entity1 . RESULTS: Eleven of 14 @entity1 underwent initial sensitization before initiating treatment. Three of these @entity1 had an eczematous reaction after 1 attempt, 5 after >= 2 attempts, and 3 failed to develop a clinical reaction. Four of 14 initiated treatment without a clinical reaction or a previous sensitization. Eleven of 14 @entity1 experienced regrowth, 7 with previous sensitization and 4 without. LIMITATIONS: This observational study is limited by sample size. CONCLUSIONS: @entity25183 sensitization regimens and reactions vary widely, and the absence of an initial  eczematous reaction to sensitization does not predict a failed response with continued @entity25183 treatment.

Squaric acid sensitization is not required for response in the treatment of XXXX areata.

@entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity25183 :: ('MESH:C020637', 'Chemical') :: ['squaric acid dibutylester', 'SADBE']
@entity1665 :: (MESH:D000505,Disease) :: ['alopecia']
